Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) Income from Continuing Operations: 2022-2024

Historic Income from Continuing Operations for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $65.6 million.

  • Entrada Therapeutics' Income from Continuing Operations fell 215.75% to -$44.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.5 million, marking a year-over-year decrease of 288.29%. This contributed to the annual value of $65.6 million for FY2024, which is 1087.80% up from last year.
  • Latest data reveals that Entrada Therapeutics reported Income from Continuing Operations of $65.6 million as of FY2024, which was up 1,087.80% from -$6.6 million recorded in FY2023.
  • Over the past 5 years, Entrada Therapeutics' Income from Continuing Operations peaked at $65.6 million during FY2024, and registered a low of -$94.6 million during FY2022.
  • In the last 3 years, Entrada Therapeutics' Income from Continuing Operations had a median value of -$6.6 million in 2023 and averaged -$11.9 million.
  • Data for Entrada Therapeutics' Income from Continuing Operations shows a peak YoY skyrocketed of 1,087.80% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Entrada Therapeutics' Income from Continuing Operations stood at -$94.6 million in 2022, then surged by 92.98% to -$6.6 million in 2023, then surged by 1,087.80% to $65.6 million in 2024.